Compare Incyte Corporation (INCY) vs Sony Group Corp (SONY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Sony Group Corp — how do they compare? Incyte Corporation trades at $112.96 (market cap $22.85B), while Sony Group Corp trades at $24.22 (market cap $136.87B). The key difference: Sony Group Corp is far larger — about 6× Incyte Corporation's market cap, and Sony Group Corp pays a 0.66% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Sony Group Corp for 96 Days on average.
| INCY | SONY | |
|---|---|---|
Market Cap | $22.85B | $136.87B |
Volume | 1,927,029 | 5,364,503 |
Sector | Health | Technology |
52-Week High | $129.93 | $30.26 |
52-Week Low | $83.80 | $19.32 |
Typical Hold Time | 33 Days | 96 Days |
Enterprise Value | $18.35B | $134.77B |
Dividend Yield | — | 0.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.44, up 0.63% with a bullish technical signal despite mixed moving averages. The company shows strong fundamentals with 2025 revenue of $5.14B, net income of $1.29B, and impressive profitability margins (gross margin 92.62%, net margin 27.71%). Recent FDA approval for Atebrioz and pipeline expansion signal growth beyond JAKAFI. Valuation appears reasonable with P/E of 14.36 and P/S of 3.98.
Outlook remains positive with analyst consensus target of $132.43 (16.7% upside) and 52% buy ratings. Key opportunities include pipeline diversification and $4B sales target, while risks involve JAKAFI patent expiration post-2029 and competitive pressures. Strong cash flow generation ($1.41B operating CF) supports continued R&D investment.
Sony trades at $24.05, up 2.25% with mixed technical signals and neutral analyst sentiment. The company reported strong Q2 2026 earnings beat but faces profitability challenges with negative net income margin and ROE. Recent news highlights Sony's content strength and legal actions against AI companies for copyright infringement.
Sony presents a mixed investment case with strong cash flow generation and content portfolio offset by near-term profitability concerns. The stock's valuation appears reasonable with P/E of 20.34, but investors should monitor the company's ability to improve margins amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Sony Group Corp
Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →
